Letter: Outcome Measure Selection as a Source of Null Results in Autism Pharmacotherapy: The Case of Brexpiprazole and the ABC-I
Journal of Child and Adolescent Psychopharmacology · 01.08.2026 · 36 (6) · 382-383
DOI: 10.1177/10445463261453242 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Child and Adolescent Psychopharmacology, online erschienen am 20.05.2026. Verfasst von Berkan Şahin. Beteiligte Einrichtung: Department of Child and Adolescent Psychiatry, Faculty of Medicine, Giresun University, Giresun, Turkey. Die Arbeit nennt 14 Literaturangaben.
Abstract (Originalsprache)
the results of a Phase 3, randomized, double-blind, placebo-controlled trial and 26-week open-label extension of brexpiprazole for irritability associated with autism spectrum disorder (ASD) in children and adolescents aged 5 – 17 years
Autor:innen und Institutionen
- Department of Child and Adolescent Psychiatry, Faculty of Medicine, Giresun University, Giresun, Turkey.
ORCID-Profile: Berkan Şahin
Zitieren
APA
Şahin, B. (2026). Letter: Outcome Measure Selection as a Source of Null Results in Autism Pharmacotherapy: The Case of Brexpiprazole and the ABC-I. Journal of Child and Adolescent Psychopharmacology, 36(6), 382-383. https://doi.org/10.1177/10445463261453242
Vancouver
Şahin B. Letter: Outcome Measure Selection as a Source of Null Results in Autism Pharmacotherapy: The Case of Brexpiprazole and the ABC-I. Journal of Child and Adolescent Psychopharmacology. 2026;36(6):382-383. doi:10.1177/10445463261453242
BibTeX
@article{ahin2026,
author = {Şahin, Berkan},
title = {Letter: Outcome Measure Selection as a Source of Null Results in Autism Pharmacotherapy: The Case of Brexpiprazole and the ABC-I},
journal = {Journal of Child and Adolescent Psychopharmacology},
year = {2026},
volume = {36},
number = {6},
pages = {382--383},
doi = {10.1177/10445463261453242}
}
EUVIMED